sequence under fasting conditions,A randomized,
Sponsors
Bio-innova and Synchron.Co.,Ltd
Conditions
Bioequivalence study in healthy volunteersBioequivalence study in healthy volunteers
Bioequivalence,
Phase 1
A single dose study under fasting condition to access the Bioequivalence of Etoricoxib 120 mg tablets (Test formulation), manufactured by Interthai Pharmaceutical Manufacturing Limited with a reference formulation Arcoxia® - MSD, in 24 healthy volunteers
Active, not recruitingTCTR20170201002
Start: 2017-02-01Updated: 2026-03-30
Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Levonorgestrel Tablet (0.75 mg) relative to POSTINOR (Original Levonorgestrel Tablet (0.75 mg)) in healthy Thai volunteers under fasting condition
Active, not recruitingTCTR20170213001
Start: 2017-02-13Updated: 2026-03-30
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Deferasirox 250 mg dispersible tablets relative to Exjade® 250 mg dispersible tablets in healthy Thai volunteers under fasting condition
Active, not recruitingTCTR20180705002
Start: 2019-01-31Target: 38Updated: 2026-03-30